Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Insulin synthesized in the paraventricular nucleus of the hypothalamus regulates pituitary growth hormone production
Jaemeun Lee, … , Yong Chul Bae, Eun-Kyoung Kim
Jaemeun Lee, … , Yong Chul Bae, Eun-Kyoung Kim
Published July 9, 2020
Citation Information: JCI Insight. 2020;5(16):e135412. https://doi.org/10.1172/jci.insight.135412.
View: Text | PDF
Research Article Endocrinology Neuroscience

Insulin synthesized in the paraventricular nucleus of the hypothalamus regulates pituitary growth hormone production

  • Text
  • PDF
Abstract

Evidence has mounted that insulin can be synthesized in various brain regions, including the hypothalamus. However, the distribution and functions of insulin-expressing cells in the hypothalamus remain elusive. Herein, we show that in the mouse hypothalamus, the perikarya of insulin-positive neurons are located in the paraventricular nucleus (PVN) and their axons project to the median eminence; these findings define parvocellular neurosecretory PVN insulin neurons. Contrary to corticotropin-releasing hormone expression, insulin expression in the PVN was inhibited by restraint stress (RS) in both adult and young mice. Acute RS–induced inhibition of PVN insulin expression in adult mice decreased both pituitary growth hormone (Gh) mRNA level and serum GH concentration, which were attenuated by overexpression of PVN insulin. Notably, PVN insulin knockdown or chronic RS in young mice hindered normal growth via the downregulation of GH gene expression and secretion, whereas PVN insulin overexpression in young mice prevented chronic RS–induced growth retardation by elevating GH production. Our results suggest that in both normal and stressful conditions, insulin synthesized in the parvocellular PVN neurons plays an important role in the regulation of pituitary GH production and body length, unveiling a physiological function of brain-derived insulin.

Authors

Jaemeun Lee, Kyungchan Kim, Jae Hyun Cho, Jin Young Bae, Timothy P. O’Leary, James D. Johnson, Yong Chul Bae, Eun-Kyoung Kim

×

Figure 4

Insulin knockdown in the PVN of adult mice reduces pituitary GH gene expression and secretion.

Options: View larger image (or click on image) Download as PowerPoint
Insulin knockdown in the PVN of adult mice reduces pituitary GH gene exp...
GFP lentiviral vector carrying nonsilencing shRNA control (shNon-silencing) or Ins2 shRNA (shRNA Ins2) was injected into the PVN of adult mice. (A) A confocal image showing colocalization of the GFP-infected cells with proinsulin in the PVN 2 weeks after the lentiviral injection. (B) qRT-PCR data showing the efficient knockdown of Ins2, but not Crh, by Ins2 shRNA in the microdissected PVN. (C and D) Confocal images of C-peptide–immunoreactive nerve terminals in the ME (C) and quantification of the fluorescence intensity (D). (E) Relative levels of the mRNA for anterior pituitary hormones in the pituitary. (F) Serum GH concentrations in tail vein samples taken 4 times a day. (G and H) Immunoblot analysis of p-Akt (Ser473), Akt, and GAPDH levels in the pituitary (G). Quantification of p-Akt levels normalized to Akt (H). (I) Relative pituitary Pit-1 mRNA levels. (J) Relative hypothalamic GH–releasing hormone (Ghrh) or Sst mRNA levels. (K and L) Serum corticosterone (K) and insulin (L) concentrations. (M and N) Changes in body weight (M) and food consumption (N) for 2 weeks after the injection. Data are shown as mean ± SEM, 2-tailed unpaired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001, n = 6–9 mice/group (B, E, F, and I–N), n = 3 or 4 mice/group (D), n = 5 mice/group (H and J). Scale bars: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts